touchONCOLOGY meets with Lori J Wirth from Harvard Medical School and Massachusetts General Hospital in Boston, MA to discuss important treatment approaches and advances for thyroid cancer, including investigating lenvatinib and major findings of the SELECT trial, and how the clinical development of new therapies such as LOXO-292 and spartalizumab may contribute to treatment paradigms moving forward.
1. What factors do you consider when selecting which patients should receive treatment for thyroid cancer? (0:11)
2. What treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine? (0:57)
3. What were the major findings of the SELECT trial investigating levantinib in differentiated thyroid cancer? (1:53)
4. What have been the most important advances in thyroid cancer research in the past year? (3:06)
5. What is the rationale for the use of LOXO-292 for the treatment of thyroid cancer? (4:52)
6. What clinical evidence to date supports the use of LOXO-292 in this application? (5:56)
7. Could you tell us a little about spartalizumab and its clinical development in anaplastic thyroid cancer? (6:32)
Speaker disclosures: Lori J Wirth has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018